Abstract
Adenocarcinoma of the esophagus, gastroesophageal junction (GEJ), or stomach with signet ring cell (SRC) features pertains a worse prognosis. Therefore, clinicians tend to have lower threshold for initiating systemic therapy in such patients given the aggressive behavior. Neoadjuvant treatment (NAT) with chemotherapy or chemoradiation (CRT) is considered the standard of care in locoregional disease. However, the benefit of NAT in patients with SRC is unclear. In this study we investigated the clinical characteristics and outcomes of patients with locoregional SRC of esophagus/stomach along with the effect of NAT on outcomes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
